Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. edor box

EDOR BOX

Electrodermal Orienting Reactivity-based Safeguard System for Early Detection of Suicide Propensity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 EDOR BOX project word cloud

Explore the words cloud of the EDOR BOX project. It provides you a very rough idea of what is the project "EDOR BOX" about.

disorder    yearly    health    97    reactivity    death    attempts    attributed    exposed    half    suicidal    revenues    emotra    youngsters    detected    patients    depressed    save    antidepressants    solution    diagnosis    overcome    economically    suicides    incurred    trials    applicability    actually    insufficient    organization    edor    subjective    company    lack    44    according    diagnostic    jobs    prescribed    global    patient    people    coming    billion    economic    innovative    detect    17    market    propensity    world    alarming    tools    expressed    sensitivity    electrodermal    device    efficacy    suicide    clinical    15    limitations    analyzes    alone    350    sweat    appallingly    million    society    adults    swedish    biomarker    detection    groups    burden    demonstrated    prevent    depression    800    attempt    age    distinguish    ultimately    absent    hyporeactivity    safety    emotionally    brain    impulses    tool    rates    prove    signals    introduction    risk    box    committing    29    healthcare    population    tests    creation    reflected    onset    audio   

Project "EDOR BOX" data sheet

The following table provides information about the project.

Coordinator		 EMOTRA AB 

Organization address
address: GOTEBORGSVAGEN 74
city: SAVEDALEN
postcode: 433 63
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website http://emotra.se/en/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMOTRA AB SE (SAVEDALEN) coordinator 50˙000.00

Map

 Project objective

According to the World Health Organization there are 800,000 suicides and 10 million attempts yearly. Appallingly, suicide is the third cause of death among 15-44 years and the second in 15-29 years old. Suicide is a major burden to society emotionally, but also economically. Costs incurred by each attempt rise to €100,000. Half reduction in the number of attempts would save €20 billion to the EU alone. Depression is the disorder most commonly attributed to suicide affecting 350 M people. Antidepressants are commonly prescribed, but they prove to be insufficient if the patient is at risk of committing suicide. However, there are no reliable tests so far to distinguish depressed patients not-at-risk, from those actually at-risk of committing suicide. In response, the Swedish company EMOTRA has developed EDOR-BOX, an innovative biomarker-based device for early detection of suicide risk. Our technology analyzes brain reactivity expressed as sweat impulses when exposed to audio signals. Absent brain responses are reflected in electrodermal hyporeactivity (no electrodermal responses), which we use as a biomarker for suicide risk in depressed patients. EDOR's main objective is to market a unique tool for effective diagnosis of suicide risk in patients from all age groups. We have already demonstrated the safety and efficacy of our device in adults, with 97% sensitivity in clinical trials. Now we aim to ensure its applicability in youngsters, due to the alarming suicide rates in this population. Our method is a cost-effective solution to prevent suicide by ensuring early detection of the risk. EDOR-BOX will provide estimated revenues of €17 M five years upon introduction, with a global impact and the creation of 50 new jobs. Ultimately, EDOR-BOX will overcome the limitations in our healthcare due to the lack of non-subjective diagnostic tools to detect an early onset of suicide propensity, as well as the economic burden coming from non-detected suicidal cases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EDOR BOX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EDOR BOX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More